238 related articles for article (PubMed ID: 15980879)
1. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.
Russell NH; Byrne JL; Faulkner RD; Gilyead M; Das-Gupta EP; Haynes AP
Bone Marrow Transplant; 2005 Sep; 36(5):437-41. PubMed ID: 15980879
[TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
Huff CA; Fuchs EJ; Smith BD; Blackford A; Garrett-Mayer E; Brodsky RA; Flinn IW; Ambinder RF; Borrello IM; Matsui WH; Vogelsang GB; Griffin CA; Luznik L; Jones RJ
Biol Blood Marrow Transplant; 2006 Apr; 12(4):414-21. PubMed ID: 16545725
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
5. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
8. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
9. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.
Klyuchnikov E; Holler E; Bornhäuser M; Kobbe G; Nagler A; Shimoni A; Könecke C; Wolschke C; Bacher U; Zander AR; Kröger N
Br J Haematol; 2012 Oct; 159(2):172-81. PubMed ID: 22909192
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
[TBL] [Abstract][Full Text] [Related]
13. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
Kobbe G; Fenk R; Neumann F; Bernhardt A; Steidl U; Kondakci M; Graef T; Aivado M; Vaupel M; Huenerlituerkoglu AN; Kronenwett R; Pape H; Hildebrand B; Germing U; Haas R
Cytotherapy; 2004; 6(6):533-42. PubMed ID: 15764020
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders.
Hertzberg M; Grigg A; Gottlieb D; Szer J; Roberts A; Hoyt R; Huang G; Bradstock KF
Bone Marrow Transplant; 2006 May; 37(10):923-8. PubMed ID: 16565735
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
Elliott MA; Tefferi A; Hogan WJ; Letendre L; Gastineau DA; Ansell SM; Dispenzieri A; Gertz MA; Hayman SR; Inwards DJ; Lacy MQ; Micallef IN; Porrata LF; Litzow MR
Bone Marrow Transplant; 2006 Jun; 37(11):1003-8. PubMed ID: 16604096
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
18. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.
Anderlini P; Acholonu SA; Okoroji GJ; Andersson BS; Couriel DR; De Lima MJ; Donato ML; Khouri IF; Giralt SA; Ueno NT; Champlin RE
Bone Marrow Transplant; 2004 Sep; 34(6):511-4. PubMed ID: 15273710
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions.
Dvorak CC; Gilman AL; Horn B; Jaroscak J; Dunn EA; Baxter-Lowe LA; Cowan MJ
Bone Marrow Transplant; 2009 Dec; 44(12):805-12. PubMed ID: 19421175
[TBL] [Abstract][Full Text] [Related]
20. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
Roberts MM; Dyson P; Rawling C; Thorp D; Rawling T; White D; Horvath N; Bardy P; Hui CH; Dart GW; To LB; Hughes TP
Cytotherapy; 2003; 5(6):534-41. PubMed ID: 14660049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]